Excaliard | GenomeWeb

Excaliard

Isis Pharmaceuticals last month responded to objections about its use of a former executive as an expert in its patent-infringement lawsuit against Santaris Pharma, arguing to the court that a purported conflict of interest does not exist and an order allowing the expert access t

This article has been updated to clarify details regarding Traversa Therapeutics' bankruptcy proceedings.

RXi Pharmaceuticals has completed patient dosing in the second of two phase I trials of its lead drug candidate, the anti-scarring agent RXI-109, and is on track to initiating a phase II study before the end of the year, the company's top executive said last week.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.